Specificity of MRI with optimal temporal, spatial, and spectral samp. for early B
Specificity of MRI with optimal temporal, spatial, and spectral samp. for early B
批准号:
7198291
负责人:
Gregory S. Karczmar
金额:
$18.68万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-11-01 至 2011-07-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Conventional magnetic resonance imaging has good sensitivity for detecting very early breast cancers, and
may be a valuable for screening women who are at high risk for breast cancer. However, its specificity is
inadequate, particularly given its high sensitivity. As a result there is a concern that MRI scans lead to
unnecessary treatment. We propose to significantly increase sensitivity and specificity with improved
spectral, temporal and spatial sampling (MRITSS). MRITSS has two components. High spectral and spatial
resolution MRI provides a high resolution water spectrum associated with each image voxel, and the water
spectral lineshape is analyzed to produce improved anatomic and functional MR images. High temporal and
spatial resolution imaging during contrast media uptake and washout allows accurate measurement of
perfusion and other physiologic parameters. We will test the hypothesis that the combination of these two
approaches - MRITSS - improves specificity and sensitivity in the high risk population that would benefit
most from MRI. We will study 'incidental' lesions that are found during clinical MRI screening, since these
lesions are most susceptible to incorrect diagnosis. An additional research scan before biopsy will acquire
data from an 'incidental lesion', using MRITSS. Conventional and MRITSS data will be evaluated using
standard morphologic and functional parameters to arrive at a diagnosis. We will determine whether
MRITSS increases specificity and sensitivity, using the pathologist's diagnosis as the gold standard. In
addition, we will determine whether MRI parameters are correlated with genetic and biologic markers for
cancer risk, including microvessel density, cell proliferation markers, VEGF receptors, and P53, HER2,
BRCA1 and BRCA2. The study will include African American women who are at particularly high risk for
aggressive early breast cancer. We will compare the MRI parameters for breast lesions in these women with
those for the other women in the study.
The research will have a significant impact on clinical managements of breast cancer. If the results
demonstrate that MRITSS has high specificity for early breast cancer- this will support increased clinical
use of MRI for screening high risk women, and integration of improved spectral, spatial, and temporal
sampling into clinical MRI. In addition, the research provides an unusual opportunity to correlate MRI
parameters with biological markers for malignancy in early breast cancers. This could lead to improved
design of MRI protocols and interpretation of MR images. The research is an interdisciplinary collaboration
between Radiologists, Oncologists, Surgeons, Pathologists, Medical Physicists, and Statisticians with strong
track records in breast imaging and breast cancer treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Detection of prostate Cancer Specific Signals with Hybrid Multi-Dimensional MRI
-
批准号:10365985
-
项目类别:
-
资助金额:$52.35万
-
财政年份:2019
-
负责人:Gregory S. Karczmar
-
依托单位:
Detection of prostate Cancer Specific Signals with Hybrid Multi-Dimensional MRI
-
批准号:10600041
-
项目类别:
-
资助金额:$52.48万
-
财政年份:2019
-
负责人:Gregory S. Karczmar
-
依托单位:
Detection of prostate Cancer Specific Signals with Hybrid Multi-Dimensional MRI
-
批准号:9906218
-
项目类别:
-
资助金额:$53.04万
-
财政年份:2019
-
负责人:Gregory S. Karczmar
-
依托单位:
Breast Cancer Screening with Quantitative Ultra-Fast DCEMRI and Clinical Risk Assessment
-
批准号:9370492
-
项目类别:
-
资助金额:$57.82万
-
财政年份:2017
-
负责人:Gregory S. Karczmar
-
依托单位:
Breast Cancer Screening with Quantitative Ultra-Fast DCEMRI and Clinical Risk Assessment
-
批准号:10174859
-
项目类别:
-
资助金额:$57.66万
-
财政年份:2017
-
负责人:Gregory S. Karczmar
-
依托单位:
3T MRI Scanner for multidisciplinary imaging and image-guided therapy
-
批准号:8733938
-
项目类别:
-
资助金额:$200.0万
-
财政年份:2014
-
负责人:Gregory S. Karczmar
-
依托单位:
Assessment of Breast Cancer Risk with High Spectral and Spatial Resolution MRI
-
批准号:9221953
-
项目类别:
-
资助金额:$48.9万
-
财政年份:2013
-
负责人:Gregory S. Karczmar
-
依托单位:
Quantitative DCEMRI of Prostate Cancer Correlation with Gold Standards
-
批准号:8422144
-
项目类别:
-
资助金额:$47.17万
-
财政年份:2013
-
负责人:Gregory S. Karczmar
-
依托单位:
Assessment of Breast Cancer Risk with High Spectral and Spatial Resolution MRI
-
批准号:8792350
-
项目类别:
-
资助金额:$48.9万
-
财政年份:2013
-
负责人:Gregory S. Karczmar
-
依托单位:
Quantitative DCEMRI of Prostate Cancer Correlation with Gold Standards
-
批准号:9273482
-
项目类别:
-
资助金额:$46.54万
-
财政年份:2013
-
负责人:Gregory S. Karczmar
-
依托单位:
Assessment of Breast Cancer Risk with High Spectral and Spatial Resolution MRI
-
批准号:8439820
-
项目类别:
-
资助金额:$49.52万
-
财政年份:2013
-
负责人:Gregory S. Karczmar
-
依托单位:
Quantitative DCEMRI of Prostate Cancer Correlation with Gold Standards
-
批准号:8881120
-
项目类别:
-
资助金额:$46.36万
-
财政年份:2013
-
负责人:Gregory S. Karczmar
-
依托单位:
Quantitative DCEMRI of Prostate Cancer Correlation with Gold Standards
-
批准号:8710106
-
项目类别:
-
资助金额:$45.05万
-
财政年份:2013
-
负责人:Gregory S. Karczmar
-
依托单位:
In Vivo Measurements of Physiologically-evoked Neuronal Currents
-
批准号:8517717
-
项目类别:
-
资助金额:$21.82万
-
财政年份:2012
-
负责人:Gregory S. Karczmar
-
依托单位:
MRI of Early Non-invasive Rodent Mammary Cancers
-
批准号:8408789
-
项目类别:
-
资助金额:$30.36万
-
财政年份:2011
-
负责人:Gregory S. Karczmar
-
依托单位:
MRI of Early Non-invasive Rodent Mammary Cancers
-
批准号:8603849
-
项目类别:
-
资助金额:$31.33万
-
财政年份:2011
-
负责人:Gregory S. Karczmar
-
依托单位:
MRI of Early Non-invasive Rodent Mammary Cancers
-
批准号:8135157
-
项目类别:
-
资助金额:$33.7万
-
财政年份:2011
-
负责人:Gregory S. Karczmar
-
依托单位:
MRIS
-
批准号:7714287
-
项目类别:
-
资助金额:$9.23万
-
财政年份:2008
-
负责人:Gregory S. Karczmar
-
依托单位:
Microvessel Density With High Spectral/Spatial MRI
-
批准号:7499018
-
项目类别:
-
资助金额:$36.53万
-
财政年份:2007
-
负责人:Gregory S. Karczmar
-
依托单位:
Microvessel Density With High Spectral/Spatial MRI
-
批准号:7678608
-
项目类别:
-
资助金额:$37.62万
-
财政年份:2007
-
负责人:Gregory S. Karczmar
-
依托单位:
海外基金